Analyst Note
| Damien Conover, CFA |Eli Lilly reported strong fourth-quarter results slightly ahead of our earnings projection, but we don’t expect any major fair value estimate changes based on the minor outperformance. The strong operating results help complement one of the strongest developing drug pipelines in the industry, reinforcing our wide moat rating.